中山大便干燥出血怎么治疗中山治痔疮大概多少钱,中山大便有血是什么回事,中山大便最后带血是怎么回事,中山华都医院贵吗好不好,中山治疗便血需要花多少钱,中山大便血水,中山痔疮微创手术疼不疼

YANGON, May 6 (Xinhua) -- A five-day Myanmar traditional medicine exhibition is underway in Myanmar's former capital of Yangon beginning Thursday, aimed at promoting the development of the country's traditional medicines and disseminating medical knowledge to the public.With over 120 booths, traditional medicine producing companies are displaying their traditional medicine products and producing accessories as well as giving traditional treating service and medical education talks.As the Myanmar traditional medicine is playing a more and more important role in treating diseases in the country, the government urges traditional medicine practitioners to protect and preserve them from depletion and extinction and to ensure their perpetual existence.Myanmar is conducting research on treatment of major diseases -- diabetes, hypertension, malaria, tuberculosis, diarrhea and dysentery through traditional medicine.To do research more effectively and on a wider scale to have the Myanmar traditional medicine standardized, the country holds traditional medicine practitioners conference every year to introduce the country's traditional medicines and its medical practices and the last conference, which was the 11th, took place in Nay Pyi Taw in December 2010.At the same time, the practitioners are also urged to strive for the promotion of the standard of Myanmar traditional medicine to reach international level.

WASHINGTON, May 11 (Xinhua) -- Johns Hopkins University researchers have demonstrated that human liver cells derived from adult cells coaxed into an embryonic state can engraft and begin regenerating liver tissue in mice with chronic liver damage.The work, published Wednesday in the journal Science Translational Medicine, suggests that liver cells derived from so- called "induced-pluripotent stem cells (iPSCs)" could one day be used as an alternative to liver transplant in patients with serious liver diseases, bypassing long waiting lists for organs and concerns about immune system rejection of donated tissue."Our findings provide a foundation for producing functional liver cells for patients who suffer liver diseases and are in need of transplantation," says Yoon-Young Jang, assistant professor of oncology at the Johns Hopkins Kimmel Cancer Center. "iPSC-derived liver cells not only can be generated in large amounts, but also can be tailored to each patient, preventing immune-rejection problems associated with liver transplants from unmatched donors or embryonic stem cells." A microsopic view shows human embryonic stem cells in various stages of differentiation into liver cells in this photo taken at Stanford University and released by the California Institute for Regenerative Medicine, March 9, 2009iPSCs are made from adult cells that have been genetically reprogrammed to revert to an embryonic stem cell-like state, with the ability to transform into different cell types. Human iPSCs can be generated from various tissues, including skin, blood and liver cells.Although the liver can regenerate in the body, end-stage liver failure caused by diseases like cirrhosis and cancers eventually destroy the liver's regenerative ability, Jang says. Currently, the only option for those patients is to receive a liver organ or liver cell transplant, a supply problem given the severe shortage of donor liver tissue for transplantation. In addition, mature liver cells and adult liver stem cells are difficult to isolate or grow in the laboratory, she says. By contrast, iPSCs can be made from a tiny amount of many kinds of tissue; and the embryonic stem- like iPSCs can grow in laboratory cultures indefinitely.For the study, Jang and colleagues generated human iPSCs from a variety of adult human cells, including liver cells, fibroblasts ( connective tissue cells), bone marrow stem cells and skin cells. They found that though the iPSCs overall were molecularly similar to each other and to embryonic stem cells, they retained a distinct molecular "signature" inherited from the cell of origin.

BEIJING, March 6 (Xinhua) -- China aims to "basically eradicate poverty" by 2020 while greatly raise its poverty line, in order to help more people in need, Chinese Premier Wen Jiabao said here Sunday.The State Council is drafting a new ten-year poverty-reduction plan (2011-2020), in which the current poverty line of 1,196 yuan per year (about 0.5 U.S. dollars a day) will be greatly raised, Wen told a panel meeting of the ongoing session of the National People's Congress (NPC).The nation will intensify its poverty alleviation efforts through aids and development, focusing on large areas of destitute population, he said to a group of NPC deputies from Gansu, one of the poorest regions in China.According to the United Nations' standard of one dollar per person each day, China still has 150 million people under the poverty line.Wen said lack of water was the bottleneck for Gansu's social-economic development, urging the province to expand the use of water conservancy technology.Wen also urged the province to coordinate economic development with environmental protection, and reverse environmental degradation in Dunhuang, a historical city with world cultural heritage threatened by decertification.

WASHINGTON, April 25 (Xinhua) -- Study by scientists at the Rockefeller University shows that anti-inflammatory drugs reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs), taken for depression and obsessive-compulsive disorder and anxiety disorders.This discovery, published online Monday in the Proceedings of the National Academy of Sciences, may explain why so many depressed patients taking SSRIs do not respond to antidepressant treatment and suggests that this lack of effectiveness may be preventable.The study may be especially significant in the case of Alzheimer's disease. Such patients commonly suffer from depression and unless this can be treated successfully, the course of the illness is likely to be more severe. Depression in the elderly is also a risk factor for developing Alzheimer's Disease and researchers have suggested that treating depression in the elderly might reduce the risk of developing the disease.In the recent study, investigators treated mice with antidepressants in the presence or absence of anti-inflammatory drugs. They then examined how the mice behaved in tasks that are sensitive to antidepressant treatment. They found that the mice's behavioral responses to antidepressants were inhibited by anti- inflammatory/analgesic treatments.They then confirmed these effects in a human population. Depressed individuals who reported anti-inflammatory drug use were much less likely to have their symptoms relieved by an antidepressant than depressed patients who reported no anti- inflammatory drug use. The effect was rather dramatic since, in the absence of any anti-inflammatory or analgesic use, 54 percent of patients responded to the antidepressant, whereas success rates dropped to approximately 40 percent for those who reported using anti-inflammatory agents."Many elderly individuals suffering from depression also have arthritic or related diseases and as a consequence are taking both antidepressant and anti-inflammatory medications. Our results suggest that physicians should carefully balance the advantages and disadvantages of continuing anti-inflammatory therapy in patients being treated with antidepressant medications," leader author Paul Greengard said.

WASHINGTON, May 11 (Xinhua) -- NASA's Dawn spacecraft has obtained its first image of the giant asteroid Vesta, which will help fine-tune navigation during its approach, the U.S. space agency announced Wednesday.Dawn expects to achieve orbit around Vesta on July 16, when the asteroid is about 117 million miles from Earth.The image from Dawn's framing cameras was taken on May 3 when the spacecraft began its approach and was approximately 752,000 miles (1.21 million km) from Vesta. The asteroid appears as a small, bright pearl against a background of stars. Vesta also is known as a protoplanet, because it is a large body that almost formed into a planet."After plying the seas of space for more than a billion miles, the Dawn team finally spotted its target," said Carol Raymond, Dawn's deputy principal investigator at NASA's Jet Propulsion Laboratory in Pasadena, California. "This first image hints of detailed portraits to come from Dawn's upcoming visit."Vesta is 330 miles (530 km) in diameter and the second most massive object in the asteroid belt. Ground- and space-based telescopes obtained images of the bright orb for about two centuries, but with little surface detail.Mission managers expect Vesta's gravity to capture Dawn in orbit on July 16. To enter orbit, Dawn must match the asteroid's path around the sun, which requires very precise knowledge of the body's location and speed. By analyzing where Vesta appears relative to stars in framing camera images, navigators will pin down its location and enable engineers to refine the spacecraft's trajectory.Dawn will start collecting science data in early August at an altitude of approximately 1,700 miles (2,700 km) above the asteroid's surface. As the spacecraft gets closer, it will snap multi-angle images allowing scientists to produce topographic maps. Dawn will later orbit at approximately 120 miles (200 km) to perform other measurements and obtain closer shots of parts of the surface. Dawn will remain in orbit around Vesta for one year. After another long cruise phase, Dawn will arrive in 2015 at its second destination, Ceres, an even more massive body in the asteroid belt.Gathering information about these two icons of the asteroid belt will help scientists unlock the secrets of our solar system's early history. The mission will compare and contrast the two giant asteroids shaped by different forces. Dawn's science instruments will measure surface composition, topography and texture. Dawn also will measure the tug of gravity from Vesta and Ceres to learn more about their internal structures. The spacecraft's full odyssey will take it on a 3-billion-mile (5-billion-km) journey, which began with its launch in September 2007.